Australia
SYMBYX, an innovative Australian med-tech startup founded in 2019, specializes in developing laser light therapy devices aimed at promoting wellness and managing chronic conditions such as Parkinson's, Fibromyalgia, and Arthritis. Their slogan, "Medical device company empowering better health with light therapy. Research-backed, ARTG & CE cleared," underscores their commitment to using non-pharmaceutical methods to enhance quality of life.
The company employs photobiomodulation to stimulate cell recovery, focusing on the gut microbiome and brain. Notably, SYMBYX has published promising results in the BMC Neurology Journal demonstrating significant improvements in Parkinson's patients. While they engage in large-scale trials in Canada and Australia, their devices are not globally available due to varying regulations.
Privately-held and boasting global partnerships, SYMBYX presents a compelling opportunity for investment in the Health Care and Medical Devices sectors. Despite no recent reported investments, their solid groundwork in research and regulatory compliance positions them as a strong player in health innovation.
